Merck & Co.'s RNAi divestiture driven by focus on core businesses strategy

Cheque books out as Merck's sale of of Sirna just one of many in core focus strategy

Merck & Co.’s divestiture of its RNA interference business (RNAi) was part of a strategy to cut $2.5bn and focus on core areas, according to its CEO.

Yesterday, reported the gene silencing pharma firm Alnylam had taken advantage of the January sales and acquired Sirna Therapeutics from Merck & Co. (known as MSD outside North America) for $175m (€128m).

Sirna was acquired by Merck in October 2006 for $1.1bn but CEO Ken Frazier was unconcerned at its drop of value at the 32nd Annual J.P. Morgan Healthcare Conference yesterday, telling investors the sale of the drug delivery subsidiary - amongst other business units - was integral to Merck’s strategy moving forward.

In October 2013, the company revealed it was looking to save $2.5bn by 2015 by reducing its network in non-core areas. “We’ve moved quickly to divest certain assets - such as Saphris [a schizophrenia treatment sold to Forest Labs] and ophthalmic products in the US [sold to Akorn in November]” he said, adding “we also recently announced the deal to divest our RNAi technology.”

Frazier named diabetes, oncology, vaccines and acute care the core focus of the new slimline Merck and Sirna and its development of novel peptides delivery vehicles using gene silencing techniques for siRNA therapeutics, did not form part of Merck's strategy going forward.

“To unlock value on our noncore areas, we assess on an ongoing basis whether particular assets are core to our strategy whether they provide comp advantage and whether they would generate greater value as part of Merck or outside Merck.”

Multi-Pharma Swap Shop?

Frazier also told stakeholders the firm was currently assessing certain other assets, days after Bloomberg reported rumours Merck was in talks with Novartis to potentially exchange its over-the-counter (OTC) consumer health unit for the Swiss firm’s animal health and human vaccine businesses.

“[The divestiture] process has intensified over the past few months and we are evaluating the role of our animal health and consumer care businesses,” he said.

“As a result we could very well reach different decisions about these two businesses. In any event we expect the process to be completed with actions reached by the end of this year.”


Merck previously told this publication the $2.5bn restructuring programme would initially focus mostly on cuts in SG&A and R&D, with certain actions affecting the sector from 2015 onwards.

Frazier did not approach the subject in his presentation, but within the last four months the firm has announced a number of plans to sell or shutter manufacturing sites in Ireland, France, Spain, the US and Puerto Rico, as well as completing the sale of a Dutch API plant to Aspen.

Related News

Bayer looking to become global OTC leader with $14.2bn acquisition

Bayer buys Merck & Co.'s OTC business for $14.2bn

Roche re-enters RNAi space with $250m Santaris acquisition

Roche re-enters gene silencing space with $250m LNA acquisition

Merck Strategises on API Production

Merck: ‘In-House API Production Remains Important Strategy’

MSD opens new China packaging facility

MSD Pushes Emerging Market Strategy With New China Packaging Facility

Merck & Co shuttering another irish facility

570 jobs to go at Merck & Co. Irish plant as part of network streamlining

Merck & Co. is closing two NJ facilities

Merck & Co.'s New Jersey rejig has some manufacturing implications

Another Merck & Co. Plant Closes

Merck & Co to Halt Production at NJ Plant and Focus on Biologics R&D

MSD uses local CMO to sell drugs in Russia's protectionist market

Merck & Co. Ups Russian Contract to Appease Pharma 2020

MSD to close Irish API Plant

For Sale: Another Merck & Co API Plant - Cost, 280 Irish Jobs

Related Products

See more related products